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An increased incidence of malignancy in patients with po-
ly/dermatomyositis (PM/DM) has been reported; several points 
remain unclear: incidence and the predictive factors for the pres-
ence of cancer and its prognosis.
Aim of the study was to evaluate the frequency of malig-
nancy among myositis patients diagnosed in our Unit in a 35 
years follow-up (from 1975 to 2010). We compared epidemio-
logical, clinical, serological and survival data of the patients 
with cancer associated myositis (CAM) with the findings of 
primary myositis, trying to define predictive factors for malig-
nancies development.
162 primary PM/DM patients were enrolled by our Rheu-
matology Unit. Diagnosis of PM/DM was based on Bohan and 
Peter criteria (1975). Myositis was considered tumor-associated 
if diagnosed within 2 years before or after the diagnosis of can-
cer. Concerning the comparison of CAM and primary myositis, 
we analyzed: age, sex, systemic symptoms (Raynaud’s phenom-
enon, dysphagia, dyspnea, fever, arthritis, dysphonia), creatine-
kinase (CK) levels at onset, autoantobodies, number of deaths, 
survival rates.
Out of 162 patients with myositis, cancer was present in 
18/72 DM patients (25%) and in 9/90 PM patients (10%). In 10 
cases the malignancy and myositis appeared simultaneously; in 
6 cases the tumor was diagnosed before and in 11 after the onset 
of myositis; cancer types more frequent were breast and ovarian 
carcinoma. Patients with CAM were older than those without 
cancer (59 yr vs. 51yr) p < 0.01. There was a female predomi-
nance in primary myositis group (M/F = 30/51 in PM and 13/41 
in DM) and in CAM-DM (6/12) while CAM-PM patients were 
equally shared.Dysphagia was more frequent in CAM than in 
primary myositis patients (37% vs. 17,5%) p < 0.035; in the 
CAM subgroup was more present in DM than PM (44% vs. 
14%) p < 0.006. Prevalence of other extramuscolar features was 
similar in the 2 subgroups.
In patients with CAM, CK medium levels were lower in 
than in primary myositis (3013 U/L vs. 2412 U/L); positive 
ENA were significantly more present in primary myositis group 
(20% vs. 7%). AntiJO1 antibodies were detectable in 6% of PM/
DM patients but not in cancer group.
22/135 (16%) with primary myositis and 15/27 patients 
with CAM (55%) died; in this second group deaths were in the 
first two years from diagnosis and in 13/15 patients were caused 
by cancer.
The survival rate of primary PM/DM at 5 years was signifi-
cantly higher (87% and 74%) compared to the CAM patients, 
where survival at 2 years was 56% for PM and 44% for DM.
The risk of cancer is significantly higher in older female 
patients with DM. Some clinical and serological features can 
be considered predictive risk factors for malignancy, although 
without  statistical  significance:  dysphagia,  lower  CK  levels, 
lower prevalence of anti-ENA antibodies.
The  overall  survival  rates  were  considerably  worse  in 
CAM; early discovery of malignancy is crucial and examina-
tions for detections of an underlying malignancy are important 
in the management of patients with PM/DM.
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The  aim  of  this  paper  is  to  demonstrate  the  ability  of 
professional teams from medical institutions in Bay of Kotor 
(Montenegro) to carry out the rehabilitation of patients with 
neuromuscular diseases in the optimal way.
A multi-year clinical course with adequate rehabilitation 
of two patients with neuromuscular disease is presented. In the 
first case, the course of the disease with rehabilitation of a boy 
diagnosed with Duchenne muscular dystrophy followed from 
his fifth to eleventh year of life is presented.
Another patient (with spinal muscular atrophy type 3) was 
followed for 3 years.
Muscular dystrophy, as a group of muscle diseases char-
acterized by progressive weakness and atrophy of the muscles 
responsible for body movements, fortunately, is not a common 
disease in the region of the Bay of Kotor.
In  first  case  an  initial  muscle  weakness  was  no-
ticed  at  age  3.  Diagnostics(high  levels  of  serum  creatine 
phosphokinase,genetical testing which confirmed the deletion 
of dystrophin gene,EMG, biopsy, and a confirmation that the 
mother is the carrier) was made in his fifth year.
Abnormality  was  noticed  during  running,  jumping  and 
standing up (with Gowers maneuver). Other development of 
weakness  in  lower  extremities,  joint  contractures,  scoliosis. 
Until the age of 10 the patient had been sent out annually to a 
stationary physical therapy professionally led with education of 
the mother. He also took adequate doses of prednisolone inter-
mittently. Since year 11 he was wheelchair-bound.
A patient with Kugelberg Welander spinal muscular at-
rophy (SMA) type 3 noticed the first symptoms (fatigue of 
gaiter muscles during walking) in age 12. After the diagnos-
tics the only possible treatment was started -physical therapy 
(in hospital and at home).He still walks independently. Other 
neuromuscular diseases are sporadic and very rarely seen in 
our region.
In neuromuscular diseases maximizing the use of rehabili-
tation procedures with all medical supplies is necessary, so that 
the patient would be able to move independently for longer.
To the satisfaction of professional teams (pediatricians, 
neurologists,physiatrists, orthopedists, physical therapists and 
medical technicians) in Montenegro, rehabilitation of patients 
with neuromuscular diseases in recent years is being organ-
ized  better  than  before,  despite  bad  socio-economic  condi-
tions. It has implemented in the special institutions located on 
the coast.166
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The cost of treatment is covered by health insurance and is 
continued in health centers, at home of patients and in the inclu-
sive school departments. Patients with neuromuscular diseases 
from other (mostly rural) areas are also allowed to rehabilitate 
in these institutions.
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Duchenne  and  Becker  muscular  dystrophies  have  similar 
signs and symptoms and are caused by different mutations in the 
same gene. The two conditions differ in their severity, age of on-
set, and rate of progression. The signs and symptoms of Becker 
muscular dystrophy are usually milder and exhibit a large range 
of variation. In most cases, muscle weakness becomes apparent 
later in childhood or adolescence and progresses at a much slower 
rate. Individuals can remain ambulatory into their 40s. Despite 
the milder skeletal muscle involvement, heart failure from dilated 
cardiomyopathy (DCM) is a common cause of morbidity and the 
most common cause of death, in the mid-40s. Two hot-spots BMD 
mutations have been described, at the 5’ end of the dystrophin 
gene, comprising exons 2 to 11 and at the 44-45 exon level.The 
most part of BMD patients present a deletion of the exons 45-48 
or 45-49. We present cardiological data – retrospectively evalu-
ated – from 16 Becker patients, aged from 7 to 52 years, sharing a 
deletion involving exon 48 alone. The mean age of the follow-up 
was 6,6 years (range 1-13,9). Cardiac function was evaluated, at 
6-month intervals, by standard and dynamic Ecg, Mono and 2D-
echocardiography, echocolor-doppler-cardiography. The following 
cardiologic parameters were considered: Heart Rate, PQ interval, 
PQ segment, QT interval, Cardiomyopathic Index, T wave anoma-
lies, presence of ectopic ventricular beats, ventricle diameters, left 
ventricular free wall and septum thickness, ejection fraction, fiber 
shortening, integrated back scattering. Data collected at the last 
control, compared with those at the time of the first control, show 
that no sign or symptom of cardiomyopathy is evident in these 
patients, suggesting that BMD patients sharing deletions limited to 
exon 48, seem to escape dystrophinopathic cardiomyopathy for a 
long time. The possible causes of such a condition are discussed.
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Non-muscle  myosin  II  (NMHC  II)  is  an  ubiquitously  ex-
pressed  protein  present  in  all  vertebrate  cells.  There  are  three 
known isoforms of NMHC II, namely NMHC II-A, II-B and II-C, 
that have a central role in cell adhesion and differentiation. NMHC 
II-A and B have been demonstrated to be present in human skeletal 
muscle and to localize to Z-lines. NMHC II-C mRNA and pro-
tein has been found widespread in human and mouse organs but 
its localization and function in human skeletal muscle have not 
been investigated. We performed single-labeling immunofluores-
cence, which showed that NMHC II-C is abundantly expressed in 
human skeletal muscle, with a transverse banding pattern of distri-
bution. By double-labeling immunofluorescence with either slow 
myosin heavy chain, desmin, α-actin or α-actinin, we localized 
NMHC II-C overlying the Z-lines and in perinuclear regions. The 
abundance of this protein in association with Z-lines suggests that 
NMHC II-C might play a role in regulating muscle contractility 
or in maintaining integrity of the myofibrillar machinery. Further 
studies need to be performed to establish the exact role of NMHC 
II-C in normal and diseased skeletal muscle.
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Multiple Acyl CoA Dehydrogenase Deficiency (MADD), also 
known as glutaric aciduria type II, is an autosomal recessively inher-
ited disorder of fatty acid metabolism which affects all the fatty-acid 
acyl-CoA dehydrogenase enzyme system. The disorder is usually 
due to defects in the genes of either alpha- or beta-subunit of electron 
transfer flavoprotein (ETFA; MIM# 231680, ETFB; MIM# 130410) 
or ETF dehydrogenase (ETFDH; MIM#231675).
Molecular defects in the ETFDH gene were found to be 
responsible for a specific sub-group of patients affected with 
a variant of the disease responsive to riboflavin (vitamin B2), 
a  precursor  of  flavin  adenine  dinucleotide  (FAD)  and  flavin 
mononucleotide (FMN) required in biological oxidation-reduc-
tion reactions. These patients are usually young adult presenting 
with proximal muscle weakness, exercise intolerance, elevated 
serum CK, cyclical vomiting and episodes of acute encepha-
lopathy, generally precipitated by an infection.
Herein, we report on a patient suffering from a riboflavin-
responsive MADD with no evidence of molecular defects in the 
ETFA, ETFB and ETFDH genes.
The patient was treated with riboflavin at the dosage of 100 
mg/day associated with a low-fatty acid diet. After six months, clin-
ical examination showed global improvement in motor functions.
Our  report  remarks  that  not  all  the  cases  of  riboflavin-
responsive MADD are due to ETFDH mutations, suggesting a 
genetic heterogeneity in this disease. As flavin binding is essen-
tial for the normal function of the Acyl CoA dehydrogenases, 
this riboflavin-responsive disease could be caused by some yet 
unidentified disorder of mitochondrial flavin metabolism and 
transport or flavoprotein homeostasis.
Anyway, in these cases, treatment with riboflavin can be 
alike effective. Therefore, early diagnosis is important to achieve 
the best treatment response.